Clinical Research

The Duke Division of Pulmonary, Allergy, and Critical Care Medicine is actively involved in clinical research that advances the understanding and treatment of patients with pulmonary dysfunction and the critically ill.

A snapshot of current clinical research in our division includes:

Duke Center for Hyperbaric Medicine and Environmental Physiology

Pulmonary researchers in this center are examining causes and treatments of pulmonary alveolar proteinosis. Patients with this rare lung disease are asked to register with the center for participation in ongoing clinical research. Learn more about how hyperbaric medicine is used to treat pulmonary alveolar proteinosis.

Interstitial Lung Disease Clinic

The Interstitial Lung Disease Clinic at Duke is participating in several multi-center clinical trials to test new and promising medications for treatment of idiopathic pulmonary fibrosis.

Interventional Pulmonology Program

Our program is actively engaged in clinical research activities to advance our knowledge about the diagnosis and treatment of airway invasion by lung cancer and malignant pleural effusions.

Lung Transplant Program

Researchers in our lung transplant program linked gastroesophageal reflux (GER) to long-term pulmonary complications after transplantation. This discovery has already led to innovative therapies to prevent and treat GER and improve patient outcomes.

Moreover, innovative translational studies have demonstrated certain genetic immune variants are protective against post-transplant rejection and have provided new insights into the mechanisms that lead to organ rejection.

Learn more about the Duke Lung Transplant Research Program.

Current Clinical Trials

The Duke Division of Pulmonary, Allergy, and Critical Care Medicine offers patients access to new therapies through participation in carefully designed clinical trials.

Current clinical research trials are being conducted in relation to the following topics. Select a research subject to learn about current trials in our division:
 
end fo content area